CFEA: a cell-free epigenome atlas in human diseases. Issue Volume 48:Issue D1(2020) (20th August 2019)

• Record Type: Journal Article
• Authors: Yu, Fulong; Li, Kai; Li, Shuangquan; Liu, Jiaqi; Zhang, Yan; Zhou, Meng; Zhao, Hengqiang; Chen, Hongyan; Wu, Nan; Liu, Zhihua; Su, Jianzhong
• Is Part Of: Nucleic acids research. Volume 48:Issue D1(2020)
• Page Start: D40
• Page End: D44
• Publication Date: 2019-08-20
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gkz715
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: Epigenetic alterations, including 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC) and nucleosome positioning (NP), in cell-free DNA (cfDNA) have been widely observed in human diseases, and many available cfDNA-based epigenome-wide profiles exhibit high sensitivity and specificity in disease detection and classification. However, due to the lack of efficient collection, standardized quality control, and analysis procedures, efficiently integrating and reusing these data remain considerable challenges. Here, we introduce CFEA (http://www.bio-data.cn/CFEA ), a cell-free epigenome database dedicated to three types of widely adopted epigenetic modifications (5mC, 5hmC and NP) involved in 27 human diseases. We developed bioinformatic pipelines for quality control and standard data processing and an easy-to-use web interface to facilitate the query, visualization and download of these cell-free epigenome data. We also manually curated related biological and clinical information for each profile, allowing users to better browse and compare cfDNA epigenomes at a specific stage (such as early- or metastasis-stage) of cancer development. CFEA provides a comprehensive and timely resource to the scientific community and supports the development of liquid biopsy-based biomarkers for various human diseases.